A promising new malaria vaccine being tested by GlaxoSmithKline is a step in the right direction, but much more economical methods are needed.
Laura Harrington, professor of entomology at Cornell University and an expert in global health and epidemiology, said that despite a resurgence in the global effort to fight malaria, the war on this deadly mosquito borne infection has overwhelmed scientists, policy makers, and government officials alike.
India, Africa Don't Get Hopes Up on Malaria Vaccine
Countries like India and Africa - hotbeds for malaria - await the world's first vaccine against the disease.
Advertisement
She said that major challenges, like behavioral and biochemical resistance by malaria vectors, and the flood of fake antimalarial drugs in the marketplace have all taken their toll.
Harrington asserted that the world's first successful malaria vaccine is almost within reach. A malaria vaccine has long been viewed as the 'holy grail of tropical medicine.'
![Potential Malaria Vaccine Triggers Optimism and Caution Among Experts in Africa]( "Potential Malaria Vaccine Triggers Optimism and Caution Among Experts in Africa")
The reaction among experts in Africa, the continent worst-hit by malaria, was optimism but also caution on Tuesday to news that the first vaccine against the killer disease may soon reach the market.
Although the GlaxoSmithKline RTS vaccine doesn't protect all immunized children - only a 46 percent reduction in malaria incidence for children 5 to 17 months, and 27 percent for those 6 to 12 weeks of age - it is better than no vaccine, and it could be used together with other strategies like vector control to reduce malaria illness and mortality.
Source: ANI
Potential Malaria Vaccine Triggers Optimism and Caution Among Experts in Africa
The reaction among experts in Africa, the continent worst-hit by malaria, was optimism but also caution on Tuesday to news that the first vaccine against the killer disease may soon reach the market.
Advertisement
Although the GlaxoSmithKline RTS vaccine doesn't protect all immunized children - only a 46 percent reduction in malaria incidence for children 5 to 17 months, and 27 percent for those 6 to 12 weeks of age - it is better than no vaccine, and it could be used together with other strategies like vector control to reduce malaria illness and mortality.
Source: ANI
GSK Hopes for Approval from EMA for Prototype Malaria Vaccine
British drug maker GlaxoSmithKline (GSK) expressed optimism that it will be approved by European regulators.
Advertisement
Malaria Vaccine Offers 100 Percent Protection by Mimicking the Effects of a Mosquito BiteA new vaccine for malaria, that supposedly imitates the effects of a mosquito bite, is offering a 100 percent protection to human volunteers, researchers claim | Advertisement
|
Advertisement
Recommended Readings
Latest Research News
New study sheds light on the intrinsic, yet often overlooked, role of sleep preparation as a hardwired survival strategy.
Microgravity-induced bone loss in space, can be reduced by systemic delivery of NELL-1, a protein required for bone growth and its maintenance.
Researchers establish connections between Alzheimer's-linked genetic alterations and the functioning of brain cells.
Team at NeuroRestore introduces a groundbreaking gene therapy that has effectively promoted nerve regrowth and reconnection, post spinal cord injury.
Scientists aim to pinpoint particular functional pathways affected by these bacteria that may have an impact on skeletal health.
